Drug Name |
Mitoxantrone hydrochloride |
Drug ID |
BADD_D01481 |
Description |
An anthracenedione-derived antineoplastic agent. |
Indications and Usage |
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis |
Marketing Status |
approved; investigational |
ATC Code |
L01DB07 |
DrugBank ID |
DB01204
|
KEGG ID |
D02166
|
MeSH ID |
D008942
|
PubChem ID |
51082
|
TTD Drug ID |
D0R3JB
|
NDC Product Code |
58598-0005; 63323-132 |
UNII |
U6USW86RD0
|
Synonyms |
Mitoxantrone | Mitozantrone | DHAQ | NSC-279836 | NSC 279836 | NSC279836 | NSC-287836 | NSC 287836 | NSC287836 | NSC-299195 | NSC 299195 | NSC299195 | NSC-301739 | NSC 301739 | NSC301739 | NSC-301739D | NSC 301739D | NSC301739D | Mitroxone | Pralifan | CL-232325 | CL 232325 | CL232325 | Mitoxantrone Acetate | Acetate, Mitoxantrone | Mitoxantrone Hydrochloride | Hydrochloride, Mitoxantrone | Novantrone | Ralenova | Novantron | Onkotrone |